

## Affidea Completes the Acquisition of Nu-Med Group in Poland



Affidea Group, a leading pan-European provider of specialist healthcare services, including cancer care, advanced diagnostic imaging and community-based polyclinics, announced today that it has successfully completed the acquisition of Nu-Med Group, a renowned cancer care provider in Poland.

This acquisition marks a key milestone in Affidea's mission to improve cancer survivorship outcomes and highlights the company's emphasis on improving patient access to integrated cancer care services - in partnership with the Polish National Health Fund (NFZ). Through this step, Affidea aims to provide a holistic approach to cancer care, from prevention and early diagnosis to advanced treatment, ensuring that patients benefit from a comprehensive and coordinated care pathway.



Nu-Med is a well-established and respected provider of comprehensive cancer care services, operating four medical centres across Poland - Elblag (North), Katowice (South), Tomaszów Mazowiecki (centre), and Zamość (East), and managing four outpatient clinics in Bełchatów, Działdowo, Iława and Ostróda. The company is known for its high clinical standards in services as radiotherapy, brachytherapy, chemotherapy, oncology consultations, advanced diagnostics and day hospitalisation.



"The integration of Nu-Med into the Affidea network is a major milestone in expanding our established cancer care footprint in Poland. We are excited to welcome Nu-Med's talented professionals, whose dedication and expertise are well-recognised across the country. This acquisition reinforces our commitment to the National Oncology Strategy, ensuring patients benefit from the highest standards of care - from prevention and early diagnosis to comprehensive treatment. Together, we will build on our strengths to improve cancer survivorship outcomes," said Mesut Göral, President of the Management Board and CEO of Affidea Poland, Senior Vice President and COO of Affidea Group.

"This is the third significant investment in cancer care that Affidea has made over the last two years, including our expansion in Switzerland with Brust Zentrum Zurich and in Romania with MedEuropa radiotherapy centres, and it brings Affidea's network to 374 centres across Europe. By integrating Nu-Med's expertise into our pan-European network, oncology services now represent a quarter of Affidea's business, working synergistically with our broader diagnostic and outpatient centres. In Poland, we work in partnership with the NFZ to offer faster and better access to high-quality cancer care services and diagnostics. Due to our scale, we are very well positioned to create an advanced platform of care that transcends national borders, ensuring that patients across Europe benefit from the highest standards of care, targeting better clinical outcomes, and improved access at a local level" said Guy Blomfield, Affidea CEO and Chairman of the Management Board.



In Poland, in addition to the acquisition of Nu-Med, at the beginning of this year, Affidea acquired the Medisport Medical Centre in Lublin, a centre specialised in orthopaedics and sports medicine, offering diagnostic imaging, specialist consultations and surgical procedures. The most recent investment was the opening of a new centre in Poznań, specialised in diagnostics and day treatment in urology and neurology. Furthermore, in 2023, the company launched the Memory Disorder Treatment Centre in Warsaw, a Centre of Excellence in neurodegenerative diseases.

"We believe that by expanding our operations across Poland, we can support our patients on a larger scale in their journey towards better health," added Mesut Göral.



Affidea Group was advised by: WKB Lawyers on legal matters, EY on financial and tax due diligence, and VCP Poland on investment banking, mergers and acquisitions. The sellers were advised by: Gide Loyrette Nouel on legal matters, BNP Paribas on investment banking, A.T. Kearney on commercial matters, and Deloitte on financial and tax services.

Source & Image Credit: Affidea

Published on: Wed, 9 Oct 2024